Novocure and Zai Lab Limited announced that the final patient has been enrolled in a Novocure-sponsored phase 2 pilot trial conducted by Zai Lab evaluating the safety and efficacy of Tumor Treating Fields (TTFields) in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. Final data collection is expected in the first half of 2022. The phase 2 pilot gastric cancer trial of TTFields has enrolled approximately 30 patients in Greater China.

The single arm, open-label, multi-center study is investigating the safety and efficacy of TTFields in combination with chemotherapy as the first-line treatment of unresectable gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma. In the study, patients receive TTFields and XELOX (capecitabine /oxaliplatin) chemotherapy until disease progression. The primary endpoint is investigator-assessed objective response rate.

The protocol is designed to include 25 evaluable patients who receive at least one tumor assessment.